CORE
🇺🇦
make metadata, not war
Services
Services overview
Explore all CORE services
Access to raw data
API
Dataset
FastSync
Content discovery
Recommender
Discovery
OAI identifiers
OAI Resolver
Managing content
Dashboard
Bespoke contracts
Consultancy services
Support us
Support us
Membership
Sponsorship
Community governance
Advisory Board
Board of supporters
Research network
About
About us
Our mission
Team
Blog
FAQs
Contact us
Filters
2 research outputs found
Treatment of Patients with Non-Hodgkin Lymphoma (NHL) with CD19/CD3 Bispecific Antibody Blinatumomab (MT103): Double-Step Dose Increase to Continuous Infusion of 60 μg/m2/d Is Tolerable and Highly Effective
Author
Andreas Viardot
Dirk Nagorsen
+12 more
Gerhard Zugmaier
Hermann Einsele
Jurgen S. Scheele
Margit Schmidt
Mariele Goebeler
Matthias Klinger
Max S Topp
Peter Kufer
Petra Klappers
Ralf Bargou
Richard Noppeney
Stefan Knop
Publication venue
'American Society of Hematology'
Publication date
Field of study
No full text
Crossref
Phase II Trial of the Anti-CD19 Bispecific T Cell–Engager Blinatumomab Shows Hematologic and Molecular Remissions in Patients With Relapsed or Refractory B-Precursor Acute Lymphoblastic Leukemia
Author
Albrecht Reichle
Andreas Viardot
+22 more
Chris Holland
Christoph Faul
Davila ML
Dieter Hoelzer
Dorothea Wessiepe
Gerhard Zugmaier
Grupp S
Heinz-August Horst
Helmut Diedrich
Hermann Einsele
Matthias Stelljes
Max S. Topp
Monika Brüggemann
Nicola Gökbuget
Noemi Mergen
Petra Klappers
Ralf C. Bargou
Reinhard Marks
Shilpa Alekar
Svenja Neumann
Topp MS
Viardot A
Publication venue
'American Society of Clinical Oncology (ASCO)'
Publication date
Field of study
No full text
Crossref